Plendil patent ruling
Mutual's ANDA for felodipine extended-release does not infringe an AstraZeneca patent for the calcium channel blocker Plendil, a D.C. federal appeals court rules Sept. 30. The court reversed a Philadelphia federal judge's ruling that Mutual infringed patent no. 4,803,081, which runs until October 2007...
You may also be interested in...
Frank Zhang, co-founder and chair of the Hong Kong-listed Chinese biotech Genscript, parent of Nasdaq-listed cell therapy star, Legend Biotech, has been detained by Chinese authorities, along with four employees.
Tests used to detect cytomegalovirus in organ transplant patients may face an easier path to market under a proposed rule that the US Food and Drug Administration released on 18 September. See what the regulatory agency said about it here.
While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere.